Once again, with more than 94% Pancreatic cancer patients carrying KRAS mutation [48] and RAS genes (KRAS, NRAS, and HRAS) were observed to interact with each other through their mutations status and gene expression [47], it is highly expected that RAS genes could be highly associated with survival outcome. This evidence concerns the gene NRAS and familial pancreatic carcinoma.